Listed Japanese companies ranked by net income attributable to owners of the parent.
81 listed companies (total ¥1.85T)
| # | Company | Net income | Revenue | Taxes paid | Total assets |
|---|---|---|---|---|---|
| 1 | Chugai Pharmaceutical Co., Ltd. | ¥434B | ¥1.26T | ¥191B | ¥2.47T |
| 2 | Otsuka Holdings Co., Ltd. | ¥363B | ¥2.47T | ¥74.0B | ¥4.20T |
| 3 | Astellas Pharma Inc. | ¥292B | ¥2.14T | ¥98.6B | ¥3.57T |
| 4 | Daiichi Sankyo Company, Limited | ¥280B | ¥2.12T | ¥128B | ¥4.00T |
| 5 | Shionogi & Co.,Ltd. | ¥205B | ¥500B | ¥41.0B | ¥2.58T |
| 6 | Sumitomo Pharma Co., Ltd. | ¥107B | ¥453B | ¥4.6B | ¥805B |
| 7 | ONO Pharmaceutical Co., Ltd. | ¥69.8B | ¥516B | ¥16.4B | ¥1.11T |
| 8 | Kyowa Kirin Co.,Ltd. | ¥67.0B | ¥497B | ¥0 | ¥1.11T |
| 9 | Eisai Co., Ltd. | ¥38.6B | ¥825B | ¥16.7B | ¥1.45T |
| 10 | Santen Pharmaceutical Co., Ltd. | ¥37.4B | ¥292B | ¥7.4B | ¥423B |
| 11 | Rohto Pharmaceutical Co., Ltd. | ¥34.2B | ¥344B | ¥11.9B | ¥486B |
| 12 | Nippon Shinyaku Co.,Ltd. | ¥29.7B | ¥171B | ¥10.2B | ¥346B |
| 13 | Tsumura & Co. | ¥28.1B | ¥193B | ¥12.6B | ¥593B |
| 14 | Kissei Pharmaceutical Co., Ltd. | ¥13.8B | ¥97.4B | ¥3.4B | ¥275B |
| 15 | SAWAI GROUP HOLDINGS Co., Ltd. | ¥10.4B | ¥202B | ¥1.8B | ¥360B |
| 16 | Zeria Pharmceutical Co., Ltd. | ¥8.5B | ¥89.2B | ¥2.7B | ¥180B |
| 17 | Mochida Pharmaceutical Co.,Ltd. | ¥7.9B | ¥117B | ¥2.4B | ¥183B |
| 18 | TAUNS Laboratories, Inc. | ¥5.5B | ¥14.4B | ¥1.8B | ¥44.6B |
| 19 | ASKA Pharmaceutical Holdings CO., Ltd. | ¥5.4B | ¥71.1B | ¥241M | ¥112B |
| 20 | TOWA Pharmaceutical Co., Ltd. | ¥5.2B | ¥274B | ¥8.5B | ¥475B |
| 21 | KOA Shoji Holdings Co., Ltd. | ¥3.7B | ¥24.7B | ¥1.9B | ¥39.5B |
| 22 | Eiken Chemical Co., Ltd. | ¥3.7B | ¥41.9B | ¥754M | ¥62.7B |
| 23 | KYORIN Pharmaceutical Co., Ltd. | ¥3.4B | ¥126B | ¥2.9B | ¥195B |
| 24 | Mizuho MEDY Co., Ltd. | ¥3.4B | ¥11.3B | ¥1.2B | ¥22.4B |
| 25 | Daito Pharmaceutical Co., Ltd. | ¥3.2B | ¥50.6B | ¥729M | ¥73.3B |
| 26 | Fuji Pharma Co.,Ltd. | ¥3.0B | ¥51.7B | ¥2.2B | ¥93.4B |
| 27 | JCR Pharmaceuticals Co.,Ltd. | ¥2.2B | ¥40.3B | ¥0 | ¥109B |
| 28 | Kaken Pharmaceutial Co., Ltd. | ¥2.1B | ¥76.9B | ¥10.7B | ¥178B |
| 29 | Fuso Pharmaceutical Industries,Ltd. | ¥2.0B | ¥62.3B | ¥1.3B | ¥90.3B |
| 30 | Seikagaku Corporation | ¥1.5B | ¥36.6B | ¥17.0M | ¥86.3B |
| 31 | Taiko Pharmaceutical Co., Ltd. | ¥923M | ¥6.4B | ¥34.0M | ¥12.3B |
| 32 | Morishita Jintan Co., Ltd. | ¥628M | ¥12.7B | ¥33.0M | ¥18.6B |
| 33 | Immuno-Biological Laboratories Co., Ltd. | ¥329M | ¥1.0B | ¥5.5M | ¥2.2B |
| 34 | YUKI Gosei Kogyo Co., Ltd. | ¥313M | ¥15.4B | ¥226M | ¥25.7B |
| 35 | RaQualia Pharma Inc. | ¥273M | — | ¥142M | ¥10.5B |
| 36 | Kohjin Bio Co., Ltd. | ¥251M | ¥4.9B | ¥228M | ¥8.9B |
| 37 | Wakamoto Pharmaceutical Co., Ltd. | ¥227M | ¥9.9B | ¥25.4M | ¥16.5B |
| 38 | Nippon Chemiphar Co., Ltd. | ¥198M | ¥33.1B | ¥105M | ¥50.0B |
| 39 | Ｈｅａｒｔｓｅｅｄ株式会社 | ¥191M | ¥3.0B | ¥107M | ¥7.7B |
| 40 | Muromachi Chemicals Inc. | ¥163M | ¥7.8B | ¥159M | ¥6.4B |
| 41 | StemCell Institute Inc. | ¥156M | ¥2.8B | ¥184M | ¥8.1B |
| 42 | Chukyoiyakuhin Co., Ltd. | ¥83.6M | ¥6.6B | ¥62.4M | ¥5.3B |
| 43 | Renascience Inc. | −¥301M | — | ¥45.2M | ¥3.5B |
| 44 | Kidswell Bio Corporation | −¥414M | ¥6.6B | ¥152M | ¥6.1B |
| 45 | 株式会社Ｖｅｒｉｔａｓ Ｉｎ Ｓｉｌｉｃｏ | −¥426M | — | ¥3.7M | ¥1.9B |
| 46 | D.Western Therapeutics Institute, Inc. | −¥632M | ¥388M | ¥1.9M | ¥2.2B |
| 47 | Kubota Pharmaceutical Holdings Co., Ltd. | −¥676M | ¥21.3M | — | ¥2.0B |
| 48 | TMS Co., Ltd | −¥716M | — | ¥950,000 | ¥2.9B |
| 49 | Perseus Proteomics Inc. | −¥718M | ¥136M | ¥3.2M | ¥1.6B |
| 50 | 株式会社サイフューズ | −¥764M | ¥231M | ¥2.5M | ¥4.3B |
| 51 | ステラファーマ株式会社 | −¥781M | ¥323M | ¥2.9M | ¥4.5B |
| 52 | ノイルイミューン・バイオテック株式会社 | −¥794M | — | ¥2.4M | ¥4.0B |
| 53 | 株式会社ＰＲＩＳＭ ＢｉｏＬａｂ | −¥834M | ¥677M | ¥1.3M | ¥3.1B |
| 54 | ソレイジア・ファーマ株式会社 | −¥876M | ¥429M | ¥0 | ¥2.1B |
| 55 | OncoTherapy Science, Inc. | −¥911M | — | ¥2.2M | ¥2.4B |
| 56 | Kringle Pharma,Inc. | −¥916M | ¥72.2M | ¥1.5M | ¥2.1B |
| 57 | 株式会社メドレックス | −¥937M | ¥128M | ¥3.2M | ¥2.2B |
| 58 | Nano Holdings, Inc. | −¥944M | ¥174M | ¥2.9M | ¥5.9B |
| 59 | Chiome Bioscience Inc. | −¥983M | ¥593M | ¥3.6M | ¥1.7B |
| 60 | K Pharma,Inc. | −¥993M | — | ¥1.6M | ¥2.9B |
| 61 | Cuorips Inc. | −¥1.0B | ¥212M | ¥2.9M | ¥5.1B |
| 62 | RIBOMIC Inc. | −¥1.1B | ¥3.0M | ¥2.4M | ¥3.0B |
| 63 | BrightPath Biotherapeutics Co., Ltd. | −¥1.3B | ¥84,000 | ¥1.9M | ¥2.6B |
| 64 | CanBas Co.,Ltd. | −¥1.3B | — | ¥1.2M | ¥1.8B |
| 65 | Delta-Fly Pharma, Inc. | −¥1.6B | — | ¥2.6M | ¥247M |
| 66 | Chordia Therapeutics,Inc | −¥1.8B | — | ¥2.4M | ¥2.7B |
| 67 | StemRIM Inc. | −¥1.9B | — | ¥8.3M | ¥5.9B |
| 68 | 株式会社ファンペップ | −¥1.9B | — | ¥3.1M | ¥2.0B |
| 69 | Oncolys BioPharma Inc. | −¥2.1B | ¥28.5M | ¥4.0M | ¥4.6B |
| 70 | Modalis Therapeutics Corporation | −¥2.2B | — | ¥950,000 | ¥3.0B |
| 71 | Carna Biosciences, Inc. | −¥2.2B | ¥579M | ¥0 | ¥1.2B |
| 72 | Healios K.K. | −¥2.2B | ¥104M | ¥4.0M | ¥17.1B |
| 73 | J-Pharma Co.,Ltd. | −¥2.5B | — | ¥5.0M | ¥4.8B |
| 74 | イノバセル株式会社 | −¥2.9B | — | ¥1.0M | ¥5.1B |
| 75 | PeptiDream Inc. | −¥3.7B | ¥18.5B | ¥8.1B | ¥77.0B |
| 76 | SanBio Company Limited | −¥3.8B | — | ¥955,000 | ¥15.6B |
| 77 | GNI Group Ltd. | −¥4.2B | ¥26.8B | ¥763M | ¥83.8B |
| 78 | SymBio Pharmaceuticals Limited | −¥4.8B | ¥1.3B | ¥12.6M | ¥3.9B |
| 79 | AnGes, Inc. | −¥5.1B | — | ¥20.6M | ¥5.4B |
| 80 | Nxera Pharma Co., Ltd. | −¥12.5B | ¥29.6B | ¥241M | ¥135B |
| 81 | Takeda Pharmaceutical Company Limited | −¥152B | ¥4.51T | ¥180B | ¥15.51T |
From the latest annual securities reports filed with EDINET. Fiscal years differ by company.